- Home
- MAZE vs CGEM Comparison
MAZE vs CGEM Comparison
Compare MAZE & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAZE
- CGEM
- Stock Information
- Founded
- MAZE 2018
- CGEM 2016
- Country
- MAZE United States
- CGEM United States
- Employees
- MAZE N/A
- CGEM N/A
- Industry
- MAZE
- CGEM Biotechnology: Pharmaceutical Preparations
- Sector
- MAZE
- CGEM Health Care
- Exchange
- MAZE NYSE
- CGEM Nasdaq
- Market Cap
- MAZE 523.1M
- CGEM 506.1M
- IPO Year
- MAZE 2025
- CGEM 2021
- Fundamental
- Price
- MAZE $9.86
- CGEM $8.69
- Analyst Decision
- MAZE Strong Buy
- CGEM Strong Buy
- Analyst Count
- MAZE 3
- CGEM 7
- Target Price
- MAZE $25.67
- CGEM $32.86
- AVG Volume (30 Days)
- MAZE 252.2K
- CGEM 533.0K
- Earning Date
- MAZE 01-01-0001
- CGEM 05-14-2025
- Dividend Yield
- MAZE N/A
- CGEM N/A
- EPS Growth
- MAZE N/A
- CGEM N/A
- EPS
- MAZE 1.25
- CGEM N/A
- Revenue
- MAZE $167,500,000.00
- CGEM N/A
- Revenue This Year
- MAZE N/A
- CGEM N/A
- Revenue Next Year
- MAZE N/A
- CGEM N/A
- P/E Ratio
- MAZE $7.07
- CGEM N/A
- Revenue Growth
- MAZE N/A
- CGEM N/A
- 52 Week Low
- MAZE $6.71
- CGEM $6.85
- 52 Week High
- MAZE $17.00
- CGEM $30.19
- Technical
- Relative Strength Index (RSI)
- MAZE N/A
- CGEM 50.76
- Support Level
- MAZE N/A
- CGEM $7.38
- Resistance Level
- MAZE N/A
- CGEM $8.39
- Average True Range (ATR)
- MAZE 0.00
- CGEM 0.51
- MACD
- MAZE 0.00
- CGEM 0.11
- Stochastic Oscillator
- MAZE 0.00
- CGEM 79.87
About MAZE MAZE THERAPEUTICS INC
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
About CGEM Cullinan Oncology Inc.
Cullinan Therapeutics Inc is a biopharmaceutical company. It has a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, creates differentiated ideas, identifies the appropriate targets, and selects the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications. It has one reporting and one operating segment, which is the business of developing immunology and oncology therapies.